Predictive BioSciences Obtains $25,000,000 Series C Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=54ef47c0-3617-4ab9-8ae7-a9b0c53529c7&Preview=1 -
Date
6/16/2010 -
Company Name
Predictive BioSciences -
Mailing Address
128 Spring Street 400 Level B Annex Lexington, MA 02421 -
Company Description
Predictive Biosciences is a molecular diagnostics company headquartered in Lexington, MA. Launched in 2006 with a $10 million Series A financing, the company was jointly founded by leading healthcare investors, experienced entrepreneurs, and internationally-renowned scientists in the areas of tumor growth, tumor angiogenesis, and cancer markers. Predictive Biosciences possesses an extensive IP portfolio – including 18 issued US patents – and deep in-house expertise in proteomics, diagnostics, oncology, and tumor biomarkers. -
Website
http://www.predictivebiosci.com -
Transaction Type
Venture Equity -
Transaction Amount
$25,000,000 -
Transaction Round
Series C -
Proceeds Purposes
Proceeds from the Series C financing will be used to complete multi-center clinical trials for Predictive’s CertNDx bladder cancer assay and support its commercial launch through the company’s CLIA certified laboratories. -
M&A Terms
-
Venture Investor
ProQuest Investments -
Venture Investor
Flybridge Capital Partners -
Venture Investor
New Enterprise Associates -
Venture Investor
Highland Capital Partners -
Venture Investor
Kaiser Permanente Ventures
